Synopsis:
Shares rose 3% following a foreign investor’s block deal. Q1FY26 revenue grew 13% despite a 39% profit decline. Strong momentum in Pharma CDMO, API, and specialty chemicals, robust project pipeline, global partnerships, and capacity expansions underpin confident FY’26 and 2030 guidance.
The shares of prominent pharmaceutical companies gained up to 3 percent in today’s morning session after a prominent foreign institutional investor acquired 1,12,492 equity shares in the company via a Block deal.
With a market capitalization of Rs 33,908.84 crore, the shares of Cohance Lifesciences Ltd were trading at Rs 882.80 per share, increasing around 0.20 percent as compared to the previous closing price of Rs 885.50 apiece.
Block deal
The shares of Cohance Lifesciences Ltd have seen positive movement after a prominent foreign institutional investor, BNP Paribas Financial Markets, acquired 1,12,492 equity shares, which is equivalent to a 0.03% stake in this CDMO company at Rs 890.75 per share, totaling Rs 10.02 crore, from Morgan Stanley Asia (Singapore) Pte.
Financial & Operational Highlights
The company’s Q1FY26 revenue grew 13% to Rs 549 crore from Rs 488 crore in Q1FY25, indicating strong top-line performance. However, net profit fell 39% to Rs 46 crore from Rs 75 crore, suggesting rising costs or margin pressures despite higher sales.
Cohance Lifesciences Ltd offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing, we are committed to providing customers with products that fulfil customer needs and expectations.
Cohance’s Q1FY26 showed steady growth across segments. Pharma CDMO revenue rose 1% YoY, or 30% after adjusting for inventory, supported by new customers and pipeline expansion. API+ grew 19%, specialty chemicals 28%, and ADCs and oligonucleotides projects progressed well. The company remains on track for its long-term USD 1 billion revenue target by 2030 with mid-30s EBITDA margins.
Cohance’s Pharma CDMO segment shows strong momentum with over 100 active projects and 16 commercial molecules. Phase III pipeline includes 9 molecules, supported by US FDA approvals and high-containment projects. Growing global innovator partnerships and RFQs reflect confidence in its integrated model, with expanded payload-linker and oligonucleotide programs driving strategic growth.
Management is confident, reaffirming both FY’26 and 2030 guidance. Key drivers include a robust project pipeline, strategic customer engagements, particularly in high-value modalities, capacity expansions in ADCs and oligos, and rising revenue from niche technologies. They are also deepening relationships with global clients, notably in Japan and the US, while bolstering leadership and advisory strength, positioning the company for sustained growth and execution excellence.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock jumps 3% after FII acquires 1,12,492 shares in the company via block deal appeared first on Trade Brains.